Agonist

An agonist is a molecule that binds to a receptor and triggers its biological signaling, mimicking the effect of the natural endogenous ligand. It is the most active pharmacological category: an agonist "switches on" the receptor and produces a measurable cellular response — muscle contraction, hormone secretion, neural modulation, gene expression. Most major therapeutic peptides (semaglutide, tirzepatide, retatrutide, liraglutide, synthetic oxytocin, GHRH analogs) are agonists at specific receptors.

Several agonist categories are distinguished by intrinsic efficacy — the maximal response they can elicit. A full agonist reaches 100% of receptor maximal response, identical to the endogenous ligand: semaglutide on the GLP-1 receptor, for example. A partial agonist produces a submaximal response (20-80%) even at receptor saturation: retatrutide is a partial agonist at the glucagon receptor, limiting counterproductive hyperglycemia while preserving thermogenic effects. An inverse agonist reduces basal activity of a constitutively active receptor — rare but relevant for some serotonergic and cannabinoid receptors. A super-agonist paradoxically exceeds the endogenous ligand maximal response through more effective structural stabilization.

Agonist potency is measured by EC50 (concentration producing 50% of maximal effect) and efficacy by Emax. A good therapeutic agonist combines potency (EC50 <1 nM, reducing required dose), selectivity (little effect on closely related receptors), and temporal profile suited to indication. Peptide agonists are particularly attractive because their sequence can be finely modulated: each amino acid at the binding interface can be substituted, allowing precise sculpting of affinity, selectivity, and duration of action.

Multi-target agonists represent the modern frontier of peptide pharmacology. Tirzepatide is a dual GLP-1/GIP agonist: a single molecule simultaneously activates two distinct receptors, combining GLP-1 satiety effects and GIP insulin sensitization. Retatrutide goes a step further with triple GLP-1/GIP/glucagon agonism: glucagon adds a thermogenic effect (brown adipose tissue activation via UCP1) and hepatic lipid mobilization, explaining record weight losses (-24.2% in Jastreboff 2023). This multi-receptor approach concentrates actions in one weekly injection that mono-target approaches cannot match.

For researchers, characterizing an agonist involves measuring its affinity (Kd in radioligand binding), functional potency (EC50 in cellular cAMP, inositol phosphate, beta-arrestin assays), selectivity (panel of related receptors), and in vivo pharmacokinetics (half-life, bioavailability, volume of distribution). The presence of a positive reference agonist (endogenous ligand) and blocking antagonist is essential to validate specificity of any observed biological response — the cornerstone of rigorous pharmacological criterion.